Expression and function of myelin expression factor 2 in hepatocellular carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Hepatocellular carcinoma (HCC) presents a significant global health challenge due to its high mortality rate and unclear pathogenesis.
• Identifying novel biomarkers is crucial for improving HCC diagnosis and patient outcomes.

Purpose of the Study:

• To investigate myelin expression factor 2 (MYEF2) as a potential diagnostic and prognostic biomarker for HCC.
• To explore the functional role of MYEF2 in HCC cell behavior.

Main Methods:

• Bioinformatic analysis using ONCOMINE, HCCDB, and THE HUMAN PROTEIN ATLAS to identify MYEF2.
• Validation using The Cancer Genome Atlas, Kaplan-Meier Plotter, COX regression, qPCR, immunohistochemistry, Western blotting, transwell, and wound healing assays.
• Assessing MYEF2 mRNA and protein expression, its association with clinical parameters, and its functional impact on HCC cell invasion and migration.

Main Results:

• MYEF2 is significantly upregulated in HCC tissues and cell lines, primarily localized in the nucleus.
• MYEF2 expression correlates with tumor stage, histological grade, and TNM stage, identifying it as an independent prognostic factor.
• Elevated MYEF2 enhances HCC cell migration and invasion, while its decrease inhibits these processes.

Conclusions:

• MYEF2 demonstrates potential as a novel biomarker for HCC diagnosis and prognosis.
• MYEF2's role in promoting HCC cell invasion and migration suggests its utility as a therapeutic target.